182 related articles for article (PubMed ID: 10232594)
41. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
[TBL] [Abstract][Full Text] [Related]
42. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
43. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
44. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
45. In vivo T cell activation properties of anti-T cell monoclonal antibodies.
Ferran C; Bach JF; Chatenoud L
Exp Nephrol; 1993; 1(2):83-9. PubMed ID: 8081961
[TBL] [Abstract][Full Text] [Related]
46. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
47. Purging of epithelial tumor cells from peripheral blood stem cells by means of the bispecific antibody BIS-1.
Schröder CP; Kroesen BJ; de Leij LF; de Vries EG
Clin Cancer Res; 2000 Jun; 6(6):2521-7. PubMed ID: 10873108
[TBL] [Abstract][Full Text] [Related]
48. Possible biological indicators of the response to recombinant tumour necrosis factor alpha in patients with advanced neoplasms.
Braczkowski R; Zubelewicz B; Romanowski W; Lissoni P; Brivio F
J Exp Clin Cancer Res; 1998 Sep; 17(3):349-54. PubMed ID: 9894774
[TBL] [Abstract][Full Text] [Related]
49. Cross-species reactivity of the anti-idiotype anti-OKT3 cascade between mice and humans.
Carreno M; Fuller L; Zucker K; Yang WC; Burke G; Nery J; Gomez C; Esquenazi V; Miller J
Hum Immunol; 1992 Apr; 33(4):249-58. PubMed ID: 1386353
[TBL] [Abstract][Full Text] [Related]
50. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells.
Carpenter PA; Pavlovic S; Tso JY; Press OW; Gooley T; Yu XZ; Anasetti C
J Immunol; 2000 Dec; 165(11):6205-13. PubMed ID: 11086054
[TBL] [Abstract][Full Text] [Related]
51. Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
Brooks D; Taylor C; Dos Santos B; Linden H; Houghton A; Hecht TT; Kornfeld S; Taetle R
Clin Cancer Res; 1995 Nov; 1(11):1259-65. PubMed ID: 9815920
[TBL] [Abstract][Full Text] [Related]
52. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
53. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
Colvin RB; Preffer FI
Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
[TBL] [Abstract][Full Text] [Related]
54. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Burges A; Wimberger P; Kümper C; Gorbounova V; Sommer H; Schmalfeldt B; Pfisterer J; Lichinitser M; Makhson A; Moiseyenko V; Lahr A; Schulze E; Jäger M; Ströhlein MA; Heiss MM; Gottwald T; Lindhofer H; Kimmig R
Clin Cancer Res; 2007 Jul; 13(13):3899-905. PubMed ID: 17606723
[TBL] [Abstract][Full Text] [Related]
55. OKT3 induction via idiotypic networks of mirror-image immunosuppressive antiimmunoglobulins in renal transplant recipients.
Carreno M; Yang WC; Esquenazi V; Fuller L; Burke G; Milgrom M; Roth D; Ranjan D; Miller J
Transplantation; 1990 Feb; 49(2):408-15. PubMed ID: 1689519
[TBL] [Abstract][Full Text] [Related]
56. Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response.
Bach JF; Chatenoud L
Transplant Proc; 1987 Apr; 19(2 Suppl 1):17-20. PubMed ID: 3105135
[No Abstract] [Full Text] [Related]
57. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.
Cole MS; Stellrecht KE; Shi JD; Homola M; Hsu DH; Anasetti C; Vasquez M; Tso JY
Transplantation; 1999 Aug; 68(4):563-71. PubMed ID: 10480417
[TBL] [Abstract][Full Text] [Related]
58. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
Herold KC; Burton JB; Francois F; Poumian-Ruiz E; Glandt M; Bluestone JA
J Clin Invest; 2003 Feb; 111(3):409-18. PubMed ID: 12569167
[TBL] [Abstract][Full Text] [Related]
59. Generation and function of human regulatory CD8+ T cells induced by a humanized OKT3 monoclonal antibody hOKT3gamma1 (Ala-Ala).
Ablamunits V; Herold KC
Hum Immunol; 2008 Nov; 69(11):732-6. PubMed ID: 18817833
[TBL] [Abstract][Full Text] [Related]
60. Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
Reynolds RD; Khojasteh A; Papermaster BW; McEntire JE
Lymphokine Res; 1986; 5 Suppl 1():S165-70. PubMed ID: 3537547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
